Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 60 , 3180 ...

Opens in a new tab or window Worries that tumor necrosis factor (TNF) inhibitors may exacerbate or even cause lung disease in patients with rheumatoid arthritis (RA) are unfounded, at least for U ...

Tumor necrosis factor alpha (TNF α) is involved in cell differentiation, mitogenesis, cytotoxic responses, inflammation, immunomodulation, and wound healing. Because of its numerous roles ...

The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis ... clinical trials that have assessed the use of TNF inhibitors in patients with AS, and briefly outlines ...

Targeted drugs for rheumatoid ... inhibitors reported decreases in pain that were an average of 4.0 points greater (95% CI ...

Investigators used Veterans Administration data to assess the relationship among rheumatoid ... rheumatoid arthritis patients treated with triple therapy or tumor necrosis factor inhibitor.

The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

tumor necrosis factor inhibitors (TNFi). The study grouped 32,098 patients with psoriasis or psoriatic arthritis (PsA) into their respective categories based on biologic treatment, which included ...